-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
ARA-290 Cibinetide 10mg is a synthetic research peptide studied in relation to erythropoietin-derived peptide research, innate repair receptor pathway models, beta-common receptor signalling, inflammatory pathway research, small nerve fibre models and tissue-response pathway research.
ARA-290 is also known as Cibinetide, PHBSP or pyroglutamate helix B surface peptide. PubChem lists Cibinetide with the molecular formula C51H84N16O21 and molecular weight of approximately 1257.3 g/mol.
This product is supplied for laboratory research use only. It is not a medicine, supplement, neuropathy product, pain product, sarcoidosis product, autoimmune product, tissue-repair product, anti-inflammatory product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | ARA-290 |
| Common research name | Cibinetide |
| Other names | ARA290, PHBSP, pyroglutamate helix B surface peptide |
| Size | 10mg |
| Product type | Research peptide |
| Research category | Innate Repair Receptor Research / Erythropoietin-Derived Peptide Research |
| Common research interest | Innate repair receptor, EPOR/CD131 pathway, inflammatory pathway models and small nerve fibre research |
| Peptide type | Synthetic 11-amino-acid peptide |
| Molecular formula | C51H84N16O21 |
| Molecular weight | Approximately 1257.3 g/mol |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, neuropathy, pain, tissue repair, immune support or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| ARA-290 / Cibinetide | Synthetic research peptide | Studied in relation to innate repair receptor and erythropoietin-derived peptide research |
| PHBSP | Pyroglutamate helix B surface peptide | Common research naming linked to erythropoietin helix B surface peptide models |
| 11-amino-acid peptide structure | Short synthetic peptide | Used in pathway research involving non-haematopoietic EPO-related signalling |
| Innate repair receptor context | EPOR/CD131 pathway research | Studied in relation to tissue-response and inflammatory pathway models |
| Molecular formula | C51H84N16O21 | Listed by PubChem for Cibinetide |
| Molecular weight | Approximately 1257.3 g/mol | Useful for laboratory concentration and molar calculation planning |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
Product identity, sequence, purity, salt form, counter-ion, assay result and batch information should always be confirmed through supplier documentation and the Certificate of Analysis. Researchers should not rely on product name alone when confirming peptide identity.
ARA-290 is studied as a non-haematopoietic erythropoietin-derived peptide. In research settings, it is commonly examined in relation to the innate repair receptor, also described in literature as a heteromeric receptor complex involving the erythropoietin receptor and the beta-common receptor subunit CD131.
This makes ARA-290 different from erythropoietin itself. Erythropoietin is strongly associated with red blood cell production and regulated medicine contexts, while ARA-290 is studied as a shorter peptide model designed around non-haematopoietic signalling pathways.
ARA-290 has also been studied in clinical research involving sarcoidosis-associated small fibre neuropathy and related nerve fibre research endpoints. A PubMed Central article describes ARA-290 as a peptide designed to activate the innate repair receptor and reports research in patients with sarcoidosis-associated small fibre neuropathy.
This should be understood as research literature context only. It should not be used as a claim that a research-use ARA-290 Cibinetide 10mg vial is approved, safe or effective for neuropathy, pain, sarcoidosis, autoimmune conditions, tissue repair, inflammation, wound healing or human treatment.
| Research Area | ARA-290 / Cibinetide |
| Main research category | Innate repair receptor research |
| Common alternative name | Cibinetide |
| Other name | PHBSP |
| Peptide length | 11 amino acids |
| Parent research context | Erythropoietin-derived peptide research |
| Receptor pathway interest | Innate repair receptor, EPOR/CD131 pathway models |
| Small nerve fibre research interest | Sarcoidosis-associated and neuropathy-related research models |
| Inflammatory pathway interest | Cytokine, tissue-response and inflammatory signalling models |
| Evidence limitation | Clinical and preclinical research context does not make research vials approved for human use |
| Product limitation | Research use only, not approved for human use |
| Feature | ARA-290 / Cibinetide | Erythropoietin |
| Research class | Synthetic EPO-derived peptide | Protein hormone |
| Common pathway focus | Innate repair receptor pathway research | Erythropoiesis and EPO receptor pathway research |
| Structure | Short 11-amino-acid peptide | Larger glycoprotein hormone |
| Main receptor discussion | EPOR/CD131 innate repair receptor context | Classical erythropoietin receptor signalling |
| Common SEO risk | Neuropathy, pain, repair and inflammation claims | Blood, endurance and performance claims |
| Safer positioning | EPO-derived innate repair receptor research peptide | Regulated hormone pathway context |
| Human-use claim | Not appropriate | Only relevant to approved medicines where applicable |
| Feature | ARA-290 / Cibinetide | BPC-157 |
| Research class | Erythropoietin-derived peptide research | Stable gastric pentadecapeptide research |
| Main pathway interest | Innate repair receptor and inflammatory pathway models | Cytoprotection, angiogenesis and gastric peptide pathway research |
| Common research overlap | Tissue-response and inflammatory pathway models | Tissue-response and wound-response pathway models |
| Common SEO risk | Neuropathy, pain relief and inflammation claims | Injury recovery and gut-healing claims |
| Safer positioning | Innate repair receptor research peptide | Gastric pentadecapeptide research peptide |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | ARA-290 / Cibinetide | KPV |
| Research class | EPO-derived 11-amino-acid peptide | Alpha-MSH-derived tripeptide |
| Main pathway interest | Innate repair receptor and inflammatory pathway models | Melanocortin and inflammatory pathway research |
| Peptide length | 11 amino acids | 3 amino acids |
| Common research context | Small nerve fibre, immune and tissue-response pathway research | Cytokine, barrier and inflammatory pathway research |
| Common SEO risk | Pain, neuropathy and autoimmune claims | Gut health, anti-inflammatory and autoimmune claims |
| Safer positioning | Innate repair receptor pathway research | KPV inflammatory pathway research |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | ARA-290 / Cibinetide | TB-500 |
| Research class | Erythropoietin-derived peptide research | Thymosin beta-4 fragment research |
| Main pathway interest | Innate repair receptor, inflammatory and small nerve fibre pathway research | Actin, cell migration and tissue-remodelling pathway research |
| Common overlap | Tissue-response research models | Tissue-response and cell migration research models |
| Common SEO risk | Pain relief, neuropathy and healing claims | Injury recovery, sports recovery and tissue repair claims |
| Safer positioning | Innate repair receptor research peptide | Thymosin beta-4 fragment research peptide |
| Human-use claim | Not appropriate | Not appropriate |
| Product | Safer Research Positioning |
| ARA-290 Cibinetide 10mg | Innate repair receptor, EPOR/CD131 and small nerve fibre pathway research |
| BPC-157 10mg | Gastric pentadecapeptide, cytoprotection and angiogenesis pathway research |
| TB-500 10mg | Thymosin beta-4 fragment, actin and cell migration pathway research |
| KPV 10mg | Alpha-MSH-derived inflammatory pathway research |
| GHK-Cu 50mg / 100mg | Copper peptide and extracellular matrix pathway research |
| SS-31 10mg | Mitochondrial membrane and cardiolipin pathway research |
These products should not be written as if they are interchangeable. ARA-290 should be positioned around Cibinetide, erythropoietin-derived peptide research and innate repair receptor pathway models, not general healing, pain relief, immune support or tissue-repair claims.
| Common Online Claim | Safer Research-Use Wording |
| Neuropathy relief | Studied in small nerve fibre and innate repair receptor pathway research models |
| Pain relief | Not an approved or appropriate product claim |
| Nerve repair | Better framed as small nerve fibre research and nerve pathway models |
| Sarcoidosis support | Only discuss as clinical research context, not a product-use claim |
| Autoimmune support | Not an approved or appropriate product claim |
| Anti-inflammatory | Better framed as inflammatory pathway research |
| Tissue repair | Better framed as tissue-response pathway research |
| Wound healing | Not an approved or appropriate product claim |
| Immune modulation | Better framed as cytokine and inflammatory signalling research |
ARA-290 Cibinetide 10mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for neuropathy, pain relief, nerve repair, sarcoidosis, diabetes-related nerve symptoms, autoimmune conditions, inflammation, tissue repair, wound healing, immune support, recovery, anti-ageing, general wellness, injection or therapeutic use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for ARA-290 Cibinetide 10mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, salt form, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 10mg Vial | Final Concentration |
| 1mL | 10mg/mL |
| 2mL | 5mg/mL |
| 2.5mL | 4mg/mL |
| 3mL | 3.33mg/mL |
| 4mL | 2.5mg/mL |
| 5mL | 2mg/mL |
| 10mL | 1mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities, treatment quantities or administration schedules.
Before handling ARA-290 Cibinetide 10mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised ARA-290 / Cibinetide peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Sequence or identity confirmation | Helps confirm the product is ARA-290 / Cibinetide |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis, peptide identity and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Product identity unclear | Possible peptide mix-up or naming confusion | Stop and confirm CoA before using |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Variant control | Store and label separately from BPC-157, TB-500, KPV and other tissue-response research products |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record product name, concentration, date, diluent and batch number |
| Identity tracking | Record ARA-290 / Cibinetide / PHBSP identity where documented |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules, neuropathy protocols, pain protocols, treatment schedules or administration guidance.
ARA-290 Cibinetide 10mg is not supplied for human or animal administration. It is a laboratory research-use product only.
Clinical research involving ARA-290 has used controlled study protocols, ethics oversight, defined inclusion criteria and formal monitoring. Those research protocols are not product-use instructions and are not transferable to research-use peptide vials, different strengths, different suppliers or non-approved products.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Peptide identity | Confirmation that the product is ARA-290 / Cibinetide |
| Alternative naming | PHBSP or other documented synonym where relevant |
| Salt form | Supplier-specific salt form or counter-ion, where documented |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 10mg vial strength matches the approved research protocol |
| Compliance check | Confirmation that no neuropathy, pain relief, tissue repair or injection wording is attached to the material |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded, storage conditions are not followed or clinical research language is copied into customer-facing product claims.
Because ARA-290 is commonly discussed online in relation to neuropathy, pain, sarcoidosis, inflammation and tissue repair, product pages should avoid wording that could be interpreted as encouraging human self-use, injection, treatment use or disease management.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Confirm peptide identity | Helps verify the product is ARA-290 / Cibinetide |
| Confirm synonym details where documented | Helps avoid naming confusion with PHBSP or related peptides |
| Confirm salt form where documented | Supports correct research calculations |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Keep clinical literature separate from product-use claims | Avoids unsafe or misleading therapeutic positioning |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a neuropathy product | Creates human-use and compliance risk |
| Never make pain relief claims | Not an approved or appropriate product claim |
| Never make sarcoidosis treatment claims | Not suitable for a research-use product page |
| Never make autoimmune support claims | Not an approved or appropriate product claim |
| Never make nerve repair claims | Better framed as small nerve fibre research only |
| Never market as an anti-inflammatory treatment | Research pathway context is not a product-use claim |
| Never make wound-healing or tissue-repair claims | Not suitable for research-use material |
| Never copy clinical trial protocols into product copy | Clinical protocols are not product-use instructions |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity, treatment quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 10mg | 1mL | 10mg/mL |
| 10mg | 2mL | 5mg/mL |
| 10mg | 2.5mL | 4mg/mL |
| 10mg | 3mL | 3.33mg/mL |
| 10mg | 4mL | 2.5mg/mL |
| 10mg | 5mL | 2mg/mL |
| 10mg | 10mL | 1mg/mL |
If a researcher adds 2mL of suitable research-grade diluent to a 10mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example, treatment example, injection example, neuropathy protocol or administration instruction.
ARA-290 is a synthetic research peptide also known as Cibinetide. It is commonly studied in relation to erythropoietin-derived peptide biology, innate repair receptor pathway models, inflammatory signalling and small nerve fibre research.
Yes. ARA-290 is commonly known as Cibinetide. PubChem lists Cibinetide with synonyms including ARA290 and PHBSP.
ARA-290 is commonly studied in relation to the innate repair receptor. Literature describes the innate repair receptor as involving the erythropoietin receptor and beta-common receptor subunit CD131, which is distinct from the classical erythropoietin receptor homodimer context.
This research product is not approved or supplied for neuropathy, pain relief, nerve repair, sarcoidosis, autoimmune conditions, inflammation, tissue repair, wound healing, injection or human administration. It should be described only as a laboratory research product.
ARA-290 has appeared in clinical research involving sarcoidosis-associated small fibre neuropathy and related research endpoints. This is controlled clinical research context only and should not be converted into a claim for research-use product vials.
No. ARA-290 is an erythropoietin-derived peptide research compound, while EPO is a larger protein hormone associated with erythropoiesis and regulated medicine contexts. They should not be treated as interchangeable.
No. ARA-290 is best positioned around innate repair receptor pathway research. BPC-157 is a gastric pentadecapeptide research peptide, and TB-500 is a thymosin beta-4 fragment research peptide.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity, salt form, sequence and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem Cibinetide compound profile | Useful background on ARA-290 / Cibinetide identity, synonyms, molecular formula and molecular weight. |
| ARA-290 sarcoidosis-associated small fibre neuropathy study | Useful clinical research context on ARA-290 and small fibre neuropathy research, while reinforcing that this does not create product-use claims. |
Research Use Only: ARA-290 Cibinetide 10mg is supplied strictly for laboratory research purposes. It is not intended for human or animal consumption, injection, therapeutic use, cosmetic use, diagnostic use, neuropathy, pain relief, nerve repair, sarcoidosis, autoimmune support, inflammation, tissue repair, wound healing, immune support, recovery, anti-ageing, body enhancement or performance enhancement. Information on this page is provided for research education and product handling context only. Always follow applicable laws, institutional procedures, supplier documentation, SDS guidance and qualified laboratory protocols.
